Moya Disease
Introduction
Moyamoya Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
<div class="infobox infobox-disease"> [^2]
Disease Name: Moya Disease [^3]
Classification: Cerebrovascular Disorder / Chronic Progressive Vasculopathy [^4]
Type: Idiopathic (Moya Disease) vs. Associated with other conditions (Moya Syndrome) [^5]
Onset: Childhood (peak 5-10 years) or adulthood (30-40 years) [^6]
Prevalence: 0.5-1 per 100,000 in East Asia; 0.1 per 100,000 in Western populations [^7]
ICD-10 Code: I67.5 [^8]
OMIM: 607151
</div>
Overview
Moya Disease is a rare, chronic, progressive cerebrovascular disorder characterized by the bilateral stenosis or occlusion of the arteries at the base of the brain (the terminal internal carotid arteries and the proximal anterior and middle cerebral arteries). The name "Moya" means "puff of smoke" in Japanese, describing the appearance of the compensating collateral vessels that form at the base of the brain<sup>[1]</sup>.
This disease leads to reduced blood flow to the brain (cerebral hypoperfusion)<sup>[1]</sup>, which can cause transient ischemic attacks (TIAs), strokes, seizures, and progressive cognitive decline. Moya primarily affects children, but adults can also be affected, with females slightly more commonly affected than males.
Epidemiology
...Moya Disease
Introduction
Moyamoya Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
<div class="infobox infobox-disease"> [^2]
Disease Name: Moya Disease [^3]
Classification: Cerebrovascular Disorder / Chronic Progressive Vasculopathy [^4]
Type: Idiopathic (Moya Disease) vs. Associated with other conditions (Moya Syndrome) [^5]
Onset: Childhood (peak 5-10 years) or adulthood (30-40 years) [^6]
Prevalence: 0.5-1 per 100,000 in East Asia; 0.1 per 100,000 in Western populations [^7]
ICD-10 Code: I67.5 [^8]
OMIM: 607151
</div>
Overview
Moya Disease is a rare, chronic, progressive cerebrovascular disorder characterized by the bilateral stenosis or occlusion of the arteries at the base of the brain (the terminal internal carotid arteries and the proximal anterior and middle cerebral arteries). The name "Moya" means "puff of smoke" in Japanese, describing the appearance of the compensating collateral vessels that form at the base of the brain<sup>[1]</sup>.
This disease leads to reduced blood flow to the brain (cerebral hypoperfusion)<sup>[1]</sup>, which can cause transient ischemic attacks (TIAs), strokes, seizures, and progressive cognitive decline. Moya primarily affects children, but adults can also be affected, with females slightly more commonly affected than males.
Epidemiology
Geographic Distribution
- Highest prevalence in East Asian populations, particularly Japan, Korea, and China
- Significantly lower incidence in Western populations
- Accounts for approximately 6% of all pediatric cerebrovascular diseases in Japan<sup>[2]</sup>
Age Distribution
- Pediatric form: Peak onset at 5-10 years
- Adult form: Peak onset at 30-40 years
- Approximately 5-10% of cases are familial
Risk Factors
- Genetic predisposition (RNF213 gene mutations)<sup>[3]</sup>
- Female sex (slight female predominance)
- Family history (5-10% of cases)
- Associated conditions in Moya syndrome
Pathophysiology
Vascular Changes
The disease is characterized by<sup>[2]</sup>:
Progressive stenosis/occlusion: Of the terminal internal carotid arteries (ICA) and proximal anterior cerebral arteries (ACA) and middle cerebral arteries (MCA)<sup>[4]</sup>
Intimal thickening: Thickening of the inner layer of blood vessels
Dilated collateral vessels: Formation of abnormal collateral networks (Moya vessels)
Loss of smooth muscle cells: In the arterial mediaMoya Vessels
The characteristic "puff of smoke" appearance comes from<sup>[4]</sup>:
- Dilated basal ganglia perforating arteries
- Leptomeningeal anastomoses
- Transdural anastomoses
- Ethmoidal collateral vessels
These collaterals are fragile and prone to hemorrhage<sup>[5]</sup>.
Hemodynamic Changes
- Reduced cerebral blood flow (CBF), particularly in the anterior circulation
- Impaired cerebrovascular autoregulation
- Increased oxygen extraction fraction
- Luxury perfusion in some regions
Classification
Moya Disease (Idiopathic)
Primary vasculopathy with no identifiable underlying cause<sup>[1]</sup>.
Moya Syndrome (Quasi-Moya)
Moya-like vascular changes associated with other conditions:
- Down syndrome
- Neurofibromatosis type 1
- Sickle cell disease
- Cranial radiation therapy
- Autoimmune diseases
- Congenital heart disease
Stages (Suzuki Staging)
| Stage | Findings |
|-------|----------|
| 1 | Terminal ICA stenosis |
| 2 | Initiation of Moya vessels |
| 3 | Prominent Moya vessels |
| 4 | Reduction of Moya vessels |
| 5 | Disappearance of Moya vessels |
| 6 | Formation of external carotid collaterals |
Clinical Features
Pediatric Presentation
- Transient ischemic attacks (TIAs): Often triggered by hyperventilation, crying, or exercise
- Ischemic stroke: Particularly in the watershed territories
- Seizures: Focal or generalized
- Headache: Recurrent, often migrainous
- Cognitive decline: Progressive decline in school performance
- Movement disorders: Especially in younger children
Adult Presentation
- Hemorrhagic stroke: More common than in children (30-40% of adult cases)<sup>[5]</sup>
- TIA or ischemic stroke: Less common than hemorrhage
- Seizures
- Cognitive impairment
- Headache
Symptoms by Region Affected
- Anterior circulation: Hemiparesis, aphasia, cognitive deficits
- Posterior circulation: Visual symptoms, vertigo, ataxia
- Watershed territories: Bilateral symptoms, transcortical motor aphasia
Diagnosis
Imaging Studies
Magnetic Resonance Imaging (MRI)
- Shows vessel dropout in the basal ganglia region
- Evidence of old or acute infarcts
- Hemorrhage in adult cases
- "Ivy sign" on FLAIR sequences (leptomeningeal enhancement)
Magnetic Resonance Angiography (MRA)
- Non-invasive visualization of the steno-occlusive changes
- Shows collateral Moya vessels
- Can be used for screening and follow-up
Conventional Angiography
- Gold standard for diagnosis
- Demonstrates the characteristic "puff of smoke" appearance
- Shows all six stages of Suzuki classification
- Evaluates collateral circulation<sup>[6]</sup>
CT Angiography (CTA)
- Useful for rapid evaluation
- Shows vessel changes and collateral circulation
Laboratory Studies
- Genetic testing: RNF213 gene mutations (particularly in Asian populations)
- Routine bloodwork: To rule out other causes
- Inflammatory markers: To exclude vasculitis
Other Tests
- Cerebrospinal fluid (CSF): Typically normal
- EEG: May show slow waves in affected regions
Treatment
Medical Management
- Antiplatelet agents: Aspirin, clopidogrel (may reduce TIA frequency)
- Anticoagulants: In selected cases (e.g., with cardioembolic risk)
- Seizure control: Antiepileptic drugs as needed
- Blood pressure management: Maintain adequate cerebral perfusion
- Avoid triggers: Hyperventilation, dehydration, extreme temperatures
Surgical Revascularization
Direct Bypass
- Superficial temporal artery (STA) to middle cerebral artery (MCA) bypass<sup>[7]</sup>
- Immediate improvement in blood flow
- Technically challenging, especially in children
- High patency rates in experienced centers
Indirect Bypass
- Encephaloduroarteriosynangiosis (EDAS)
- Encephalomyosynangiosis (EMS)
- Multiple burr holes
- Safer in children
- Gradual revascularization over months
Combined Approach
- Both direct and indirect bypass
- Often performed in adult patients
Postoperative Care
- Blood pressure monitoring and management
- Antiplatelet therapy
- Serial imaging to assess bypass patency
- Rehabilitation for stroke-related deficits
Prognosis
Natural History
- Progressive disease in most cases
- Approximately 5-10% of patients remain stable
- Higher risk of stroke in patients with frequent TIAs
Prognostic Factors
- Better prognosis: Younger age at onset, STA-MCA bypass surgery<sup>[8]</sup>
- Worse prognosis: Frequent TIAs, advanced Suzuki stage, hemorrhage at presentation
Long-Term Outcomes
- Cognitive outcomes depend on timing of intervention
- Recurrent strokes can lead to permanent neurological deficits
- Quality of life generally good after successful revascularization
Associated Conditions
Moya syndrome can be associated with:
- Down syndrome
- Neurofibromatosis type 1
- Sickle cell disease
- Thalassemia
- Craniofacial syndromes
- Autoimmune vasculitis
- Antiphospholipid syndrome
- Thyroid disease
Research Directions
Genetic Studies
- RNF213 gene identification
- Understanding genotype-phenotype relationships
- Family screening protocols
Biomarkers
- Serum and CSF markers of disease activity
- Predictors of disease progression
Treatment Advances
- Novel revascularization techniques
- Medical therapies to slow progression
- Stem cell therapies
See Also
- [Stroke](/diseases/stroke)
- [Transient Ischemic Attack](/diseases/transient-ischemic-attack)
- [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy)
- [Vascular Dementia](/diseases/vascular-dementia)
- [Neurofibromatosis Type 1](/diseases/neurofibromatosis)
External Links
- [Moya Foundation](https://www.moya.org/)
- [National Institute of Neurological Disorders and Stroke (NINDS)](https://www.ninds.nih.gov/health-information/disorders/moya-disease)
- [Moya Research Bank](https://www.moyamoyaresearch.org/)
Background
The study of Moyamoya Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
- [High flow, at a higher cost? A pilot study comparing direct vs. indirect bypass for Moyamoya disease using time-driven activity-based costing.](https://pubmed.ncbi.nlm.nih.gov/41671786/) (2026 May) - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
- [Differentially expressed circular RNA profile in hemorrhagic and ischemic moyamoya disease.](https://pubmed.ncbi.nlm.nih.gov/41769189/) (2026 Apr) - Biomedical reports
- [Understanding stroke risk phenotypes in pediatric patients with sickle cell disease and concurrent moyamoya arteriopathy: insights from 61 cases at a single institution.](https://pubmed.ncbi.nlm.nih.gov/41825074/) (2026 Mar 13) - Journal of neurosurgery. Pediatrics
- [Management of pediatric patients with moyamoya arteriopathy and middle aortic syndrome: a retrospective single-institution case series.](https://pubmed.ncbi.nlm.nih.gov/41825070/) (2026 Mar 13) - Journal of neurosurgery. Pediatrics
- [Letter: Effects of Scalp Nerve Block on Symptomatic Cerebral Hyperperfusion Syndrome After Combined Revascularization Surgery for Moyamoya Disease.](https://pubmed.ncbi.nlm.nih.gov/41804911/) (2026 Mar 10) - Journal of neurosurgical anesthesiology
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data
References
[^8]: [Reference missing - citation needed]
[^7]: [Reference missing - citation needed]
[^6]: [Reference missing - citation needed]
[^5]: [Reference missing - citation needed]
[^4]: [Reference missing - citation needed]
[^3]: [Reference missing - citation needed]
[^2]: [Reference missing - citation needed]
[^1]: [Reference missing - citation needed]